Special Issue "Current Trends and Challenges in Liposomal Drug Delivery in Cancer Therapy"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 March 2023) | Viewed by 233

Special Issue Editor

Chemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt
Interests: drug delivery; the chemical modification of polymeric nanocarriers; the design and synthesis of coupling reagents and α-amino protecting groups used in peptide synthesis (application in solution and solid phase synthesis); the synthesis of biologically active heterocyclic compounds

Special Issue Information

Dear Colleagues,

The nanomedicine-based delivery of anticancer therapeutics, as well as theranostic agents, has recently established a paramount investigation. Inspired by the FDA-approved nanomedicine-based products in the market, striving for a biocompatible, biodegradable, tunable, and less immunogenic nano-system has been considered the main target. One of the most implemented nano-systems is “Liposomes”. A phospholipid bilayer self-assembled into a nanocarrier, which possesses the ability to accommodate various cargos. More importantly, the tunable characteristics of liposomes have provided an appealing resort for in vivo applications. Liposomes can be manufactured with inherent characteristics, functionalized with chemically inert or biologically derived materials. Implications pertaining to liposomal formulations encompass stimuli-responsive drug release, combined drug delivery, overcoming cancer drug resistance, gene and vaccine delivery with higher stability, as well as cancer immunotherapy. Thereby, this Special Issue aims to highlight the most recent advances in anticancer research by exploiting the full potential of liposomal nanocarriers.

I/We look forward to receiving your contributions.

Prof. Dr. Sherine N. Khattab
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • liposomes
  • cancer
  • nanomedicine
  • drug delivery
  • nanoparticles
  • drug carriers

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop